23
Oct

The newly public Vitae reported after the market closed on Thursday that the oral BI1181181/VTP-37948 hit the goal posts on a key biomarker for BACE, or beta secretase, flushing a prime suspect behind the disease without triggering any red safety flags in a pair of Phase I studies among a small group of healthy volunteers.

…read more

Source: Boehringer, Vitae survive first clinical challenge in a crowded Alzheimer’s race

    

0 No comments